Abnormalities of p51, p53, FLT3 and N-ras genes and their prognostic value in relapsed acute myeloid leukemia

Journal of Nippon Medical School

Volumn 71, Issue 4, 2004, Pages 270-278

  Nakamura, Hiroyuki ^a   Inokuchi, Koiti ^a   Yamaguchi, Hiroki ^a   Dan, Kazuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Acute myeloid leukemia; Gene mutation; Prognosis; Relapse

Indexed keywords

FLT3 LIGAND; PROTEIN; PROTEIN P51; PROTEIN P53; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MALE; ONCOGENE N RAS; POINT MUTATION; PROGNOSIS;

ADULT; AGED; DNA-BINDING PROTEINS; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENES, P53; GENES, RAS; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MUTATION; PHOSPHOPROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 4544243925     PISSN: 13454676     EISSN: None     Source Type: Journal    
DOI: 10.1272/jnms.71.270     Document Type: Article

References (26)

1. Löwenberg B, Downing JR, Burnett A: Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
2. Gripe LD, Hinton S: Acute myeloid leukemia in adults. Curr Treat Options Oncol 2000; 1: 9-17.
3. Estey E, Keating MJ, Pierce S, Stass S: Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia 1995; 9: 972-976.
4. Hu G, Zhang W, Deisseroth AB: p53 gene mutations in acute myelogenous leukaemia. Br J Haematol 1992; 81: 489-494.
5. Nakano Y, Kiyoi H, Miyawaki S, Asou N, Ohno R, Saito H, Naoe T: Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol 1999; 104: 659-664.
6. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, Ikawa S: Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998; 4: 839-843.
7. Yamaguchi H, Inokuchi K, Sakuma Y, Dan K: Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. Leukemia 2001; 15: 1729-1734.
8. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994; 57: 1-9.
9. Preudhomme C, Fenaux P: The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. Br J Haematol 1997; 98: 502-511.
10. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-3157.
11. Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, Witte L, Burrow C, Ratajczak MZ, Gewirtz AM, Civin CI: STK-1. the human homolog of Flk-2/Flt-3, is selectively expressed in CD 34 + human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1994; 91: 459-463.
12. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R: Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-3080.
13. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kahsima K, Matsuo Y, Naoe T: Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997; 11: 1605-1609.
14. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
15. Radich JP, Kopecky KJ, Willman CL, Weick J, Head D, Appelbaum F, Collins SJ: N-ras mutations in adult de novo acute myelogenous leukemia: prevelance and clinical significance. Blood 1990; 76: 801-807.
16. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, Mayer RJ, Ball ED, Wurster-Hill D, Bloomfield CD, Liu ET: Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994; 83: 1603-1611.
17. Fialkow PJ, Janssen JW, Bartram CR: Clonal remissions in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancy. Blood 1991; 77: 1415-1417.
18. Gilliland DG: Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002; 39 Suppl 3: 6-11.
19. Inokuchi K, Yamaguchi H, Hanawa H, Tanosaki S, Nakamura K, Tarusawa M, Miyake K, Shimada T, Dan K: Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia. Clin Cancer Res 2002; 8: 1882-1888.
20. Inokuchi K, Amuro N, Futaki M, Dan K, Shinohara T, Kuriya S, Okazaki T, Nomura T: Transforming genes and chromosome aberrations in therapy-related leukemia and myelodysplastic syndrome. Ann Hematol 1991; 62: 211-216.
21. Sunahara M, Shishikura T, Takahashi M, Todo S, Yamamoto N, Kimura H, Kato S, Ishioka C, Ikawa S, Ikawa Y, Nakagawara A: Mutational analysis of p51 A/TAp63γ a p53 homolog, in non-small cell lung cancer and breast cancer. Oncogene 1999; 18: 3761-3765.
22. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5: 874-879.
23. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, Takeshita A, Saito K, Hasegawa S, Shimodaira S, Tamura J, Shimazaki C, Matsue K, Kobayashi H, Arima N, Suzuki R, 7orishita H, Saito H, Ueda R, Ohno R: Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia 1997; 11: 1447-1452.
24. Abo J, Inokuchi K, Dan K, Nomura T: p53 and N-ras mutations in two new leukemia cell lines established from a patient with multilineage CD7-positive acute leukemia. Blood 1993; 82: 2829-2836.
25. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN, Kuo MC, Lai CL, Hsu HC: Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002; 100: 2387-2392.
26. Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC: Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002; 100: 2393-2398.